{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T11:10:23Z","timestamp":1729336223578,"version":"3.27.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,19]]},"DOI":"10.7759\/cureus.71844","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T10:35:09Z","timestamp":1729334109000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Sacubitril\/Valsartan in a Patient With Heart Failure and Impaired Secretion of Atrial Natriuretic Peptide Due to Long-Standing Persistent Atrial Fibrillation"],"prefix":"10.7759","author":[{"given":"Satoshi","family":"Kurisu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051195","article-title":"Myocardial metabolism in heart failure with preserved ejection fraction","volume":"13","author":"Henry JA","year":"2024","unstructured":"Henry JA, Couch LS, Rider OJ. Myocardial metabolism in heart failure with preserved ejection fraction. J Clin Med. 2024, 13:1195. 10.3390\/jcm13051195","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101027","article-title":"Long-term outcomes of heart\u00a0failure with preserved or mid-range ejection\u00a0fraction in the United States","volume":"3","author":"Sun LA","year":"2024","unstructured":"Sun LA, Dayer VW, Hansen RN, et al.. Long-term outcomes of heart\u00a0failure with preserved or mid-range ejection\u00a0fraction in the United States. JACC Adv. 2024, 3:101027. 10.1016\/j.jacadv.2024.101027","journal-title":"JACC Adv"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jce.16209","article-title":"Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: a systematic review and meta-analysis","volume":"35","author":"Kroshian G","year":"2024","unstructured":"Kroshian G, Joseph J, Kinlay S, Peralta AO, Hoffmeister PS, Singh JP, Yuyun MF. Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: a systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2024, 35:715-26. 10.1111\/jce.16209","journal-title":"J Cardiovasc Electrophysiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae218","article-title":"Clinical impact of atrial fibrillation progression in patients with heart failure with preserved ejection fraction: a report from the CHART-2 Study","volume":"26","author":"Ito T","year":"2024","unstructured":"Ito T, Noda T, Nochioka K, et al.. Clinical impact of atrial fibrillation progression in patients with heart failure with preserved ejection fraction: a report from the CHART-2 Study. Europace. 2024, 26:euae218. 10.1093\/europace\/euae218","journal-title":"Europace"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.656","article-title":"Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy","volume":"19","author":"D\u00edez J","year":"2017","unstructured":"D\u00edez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail. 2017, 19:167-76. 10.1002\/ejhf.656","journal-title":"Eur J Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-8703(98)70088-2","article-title":"Atrial natriuretic peptide in patients with heart failure and chronic atrial fibrillation: role of duration of atrial fibrillation","volume":"135","author":"Van Den Berg MP","year":"1998","unstructured":"Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, Van Gelder IC, De Kam PJ, Lie KI. Atrial natriuretic peptide in patients with heart failure and chronic atrial fibrillation: role of duration of atrial fibrillation. Am Heart J. 1998, 135:242-4. 10.1016\/s0002-8703(98)70088-2","journal-title":"Am Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s1388-9842(01)00232-x","article-title":"Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure","volume":"4","author":"van den Berg MP","year":"2002","unstructured":"van den Berg MP, Tjeerdsma G, Jan de Kam P, Boomsma F, Crijns HJ, van Veldhuisen DJ. Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure. Eur J Heart Fail. 2002, 4:255-62. 10.1016\/s1388-9842(01)00232-x","journal-title":"Eur J Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eupc.2004.04.006","article-title":"Depletion of atrial natriuretic peptide during longstanding atrial fibrillation","volume":"6","author":"van den Berg MP","year":"2004","unstructured":"van den Berg MP, van Gelder IC, van Veldhuisen DJ. Depletion of atrial natriuretic peptide during longstanding atrial fibrillation. Europace. 2004, 6:433-7. 10.1016\/j.eupc.2004.04.006","journal-title":"Europace"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon SD","year":"2019","unstructured":"Solomon SD, McMurray JJ, Anand IS, et al.. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019, 381:1609-20. 10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/biology11071034","article-title":"B-type natriuretic peptide (BNP) revisited-is BNP still a biomarker for heart failure in the angiotensin receptor\/neprilysin inhibitor era?","volume":"11","author":"Nishikimi T","year":"2022","unstructured":"Nishikimi T, Nakagawa Y. B-type natriuretic peptide (BNP) revisited-is BNP still a biomarker for heart failure in the angiotensin receptor\/neprilysin inhibitor era?. Biology (Basel). 2022, 11:1034. 10.3390\/biology11071034","journal-title":"Biology (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.09.046","article-title":"Pathophysiology, echocardiographic diagnosis, and treatment of atrial functional mitral regurgitation: JACC state-of-the-art review","volume":"80","author":"Farhan S","year":"2022","unstructured":"Farhan S, Silbiger JJ, Halperin JL, et al.. Pathophysiology, echocardiographic diagnosis, and treatment of atrial functional mitral regurgitation: JACC state-of-the-art review. J Am Coll Cardiol. 2022, 80:2314-30. 10.1016\/j.jacc.2022.09.046","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-17-1334","article-title":"Prevalence and prognostic significance of functional mitral and tricuspid regurgitation despite preserved left ventricular ejection fraction in atrial fibrillation patients","volume":"82","author":"Abe Y","year":"2018","unstructured":"Abe Y, Akamatsu K, Ito K, et al.. Prevalence and prognostic significance of functional mitral and tricuspid regurgitation despite preserved left ventricular ejection fraction in atrial fibrillation patients. Circ J. 2018, 82:1451-8. 10.1253\/circj.CJ-17-1334","journal-title":"Circ J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11748-020-01483-3","article-title":"Efficacy of left atrial plication for atrial functional mitral regurgitation","volume":"69","author":"Matsumori M","year":"2021","unstructured":"Matsumori M, Kawashima M, Aihara T, et al.. Efficacy of left atrial plication for atrial functional mitral regurgitation. Gen Thorac Cardiovasc Surg. 2021, 69:458-65. 10.1007\/s11748-020-01483-3","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11748-021-01629-x","article-title":"Surgical considerations for atrial functional regurgitation of the mitral and tricuspid valves based on the etiological mechanism","volume":"69","author":"Shibata T","year":"2021","unstructured":"Shibata T, Takahashi Y, Fujii H, Morisaki A, Abe Y. Surgical considerations for atrial functional regurgitation of the mitral and tricuspid valves based on the etiological mechanism. Gen Thorac Cardiovasc Surg. 2021, 69:1041-9. 10.1007\/s11748-021-01629-x","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-21-0795","article-title":"Left atrial myopathy in heart failure with preserved ejection fraction","volume":"87","author":"Omote K","year":"2023","unstructured":"Omote K, Borlaug BA. Left atrial myopathy in heart failure with preserved ejection fraction. Circ J. 2023, 87:1039-46. 10.1253\/circj.CJ-21-0795","journal-title":"Circ J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(91)90601-5","article-title":"Disturbed secretion of atrial natriuretic peptide in patients with persistent atrial standstill: endocrinologic silence","volume":"18","author":"Seino Y","year":"1991","unstructured":"Seino Y, Shimai S, Ibuki C, Itoh K, Takano T, Hayakawa H. Disturbed secretion of atrial natriuretic peptide in patients with persistent atrial standstill: endocrinologic silence. J Am Coll Cardiol. 1991, 18:459-63. 10.1016\/0735-1097(91)90601-5","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1536\/jhj.45.93","article-title":"Angiotensin-converting enzyme inhibitors are not effective at inhibiting further fibrous changes in the atria in patients with chronic atrial fibrillation: speculation from analysis of the time course of fibrillary wave amplitudes","volume":"45","author":"Hirayama Y","year":"2004","unstructured":"Hirayama Y, Atarashi H, Kobayashi Y, Takano T. Angiotensin-converting enzyme inhibitors are not effective at inhibiting further fibrous changes in the atria in patients with chronic atrial fibrillation: speculation from analysis of the time course of fibrillary wave amplitudes. Jpn Heart J. 2004, 45:93-101. 10.1536\/jhj.45.93","journal-title":"Jpn Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1253\/jcj.65.375","article-title":"Relation of fibrillatory wave amplitude with hemostatic abnormality and left atrial appendage dysfunction in patients with chronic nonrheumatic atrial fibrillation","volume":"65","author":"Nakagawa K","year":"2001","unstructured":"Nakagawa K, Hirai T, Shinokawa N, et al.. Relation of fibrillatory wave amplitude with hemostatic abnormality and left atrial appendage dysfunction in patients with chronic nonrheumatic atrial fibrillation. Jpn Circ J. 2001, 65:375-80. 10.1253\/jcj.65.375","journal-title":"Jpn Circ J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-009-9398-3","article-title":"Clinical value of fibrillatory wave amplitude on surface ECG in patients with persistent atrial fibrillation","volume":"26","author":"Nault I","year":"2009","unstructured":"Nault I, Lellouche N, Matsuo S, et al.. Clinical value of fibrillatory wave amplitude on surface ECG in patients with persistent atrial fibrillation. J Interv Card Electrophysiol. 2009, 26:11-9. 10.1007\/s10840-009-9398-3","journal-title":"J Interv Card Electrophysiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/156330","article-title":"Atrial functional mitral regurgitation: insufficiently understood and recognized","volume":"31","author":"Flachskampf FA","year":"2022","unstructured":"Flachskampf FA. Atrial functional mitral regurgitation: insufficiently understood and recognized. Adv Clin Exp Med. 2022, 31:1177-81. 10.17219\/acem\/156330","journal-title":"Adv Clin Exp Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.12.044","article-title":"B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction","volume":"61","author":"van Veldhuisen DJ","year":"2013","unstructured":"van Veldhuisen DJ, Linssen GC, Jaarsma T, et al.. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013, 61:1498-506. 10.1016\/j.jacc.2012.12.044","journal-title":"J Am Coll Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13042","article-title":"Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy","volume":"7","author":"Matsumoto S","year":"2020","unstructured":"Matsumoto S, Nakazawa G, Ohno Y, et al.. Efficacy of exogenous atrial natriuretic peptide in patients with heart failure with preserved ejection fraction: deficiency of atrial natriuretic peptide and replacement therapy. ESC Heart Fail. 2020, 7:4172-81. 10.1002\/ehf2.13042","journal-title":"ESC Heart Fail"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez EJ","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al.. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019, 380:539-48. 10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytz108","article-title":"Evolution of B-type natriuretic peptide and N-terminal pro-brain natriuretic peptide during acute decompensated heart failure in a chronic heart failure patient with reduced ejection fraction treated with Sacubitril\/Valsartan: a\u00a0case report","volume":"3","author":"Tiepolo A","year":"2019","unstructured":"Tiepolo A, Nougu\u00e9 H, Damoisel C, Launay JM, Vodovar N, Mebazaa A. Evolution of B-type natriuretic peptide and N-terminal pro-brain natriuretic peptide during acute decompensated heart failure in a chronic heart failure patient with reduced ejection fraction treated with Sacubitril\/Valsartan: a\u00a0case report. Eur Heart J Case Rep. 2019, 3:ytz108. 10.1093\/ehjcr\/ytz108","journal-title":"Eur Heart J Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/305509-efficacy-of-sacubitrilvalsartan-in-a-patient-with-heart-failure-and-impaired-secretion-of-atrial-natriuretic-peptide-due-to-long-standing-persistent-atrial-fibrillation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T10:35:10Z","timestamp":1729334110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/305509-efficacy-of-sacubitrilvalsartan-in-a-patient-with-heart-failure-and-impaired-secretion-of-atrial-natriuretic-peptide-due-to-long-standing-persistent-atrial-fibrillation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.71844","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,19]]}}}